文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Tim-3 的共刺激活性需要 Akt 和 MAPK 信号转导及其向免疫突触的募集。

The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse.

机构信息

Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Asahi Kasei Pharma Corporation, Shizuoka, Japan.

出版信息

Sci Signal. 2021 Jun 15;14(687):eaba0717. doi: 10.1126/scisignal.aba0717.


DOI:10.1126/scisignal.aba0717
PMID:34131021
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9741863/
Abstract

Expression of the transmembrane protein Tim-3 is increased on dysregulated T cells undergoing chronic activation, including during chronic infection and in solid tumors. Thus, Tim-3 is generally thought of as an inhibitory protein. We and others previously reported that under some circumstances, Tim-3 exerts paradoxical costimulatory activity in T cells (and other cells), including enhancement of the phosphorylation of ribosomal S6 protein. Here, we examined the upstream signaling pathways that control Tim-3-mediated increases in phosphorylated S6 in T cells. We also defined the localization of Tim-3 relative to the T cell immune synapse and its effects on downstream signaling. Recruitment of Tim-3 to the immune synapse was mediated exclusively by the transmembrane domain, replacement of which impaired the ability of Tim-3 to costimulate T cell receptor (TCR)-dependent S6 phosphorylation. Furthermore, enforced localization of the Tim-3 cytoplasmic domain to the immune synapse in a chimeric antigen receptor still enabled T cell activation. Together, our findings are consistent with a model whereby Tim-3 enhances TCR-proximal signaling under acute conditions.

摘要

跨膜蛋白 Tim-3 的表达在经历慢性激活的失调 T 细胞中增加,包括在慢性感染和实体瘤中。因此,Tim-3 通常被认为是一种抑制蛋白。我们和其他人之前曾报道过,在某些情况下,Tim-3 在 T 细胞(和其他细胞)中发挥矛盾的共刺激活性,包括增强核糖体 S6 蛋白的磷酸化。在这里,我们研究了控制 Tim-3 介导的 T 细胞中磷酸化 S6 增加的上游信号通路。我们还定义了 Tim-3 相对于 T 细胞免疫突触的定位及其对下游信号的影响。Tim-3 向免疫突触的募集完全由跨膜结构域介导,该结构域的替换损害了 Tim-3 刺激 TCR 依赖性 S6 磷酸化的能力。此外,在嵌合抗原受体中将 Tim-3 的细胞质结构域强制定位到免疫突触仍然能够激活 T 细胞。总之,我们的研究结果与一种模型一致,即在急性条件下,Tim-3 增强 TCR 近端信号。

相似文献

[1]
The costimulatory activity of Tim-3 requires Akt and MAPK signaling and its recruitment to the immune synapse.

Sci Signal. 2021-6-15

[2]
Phosphotyrosine-dependent coupling of Tim-3 to T-cell receptor signaling pathways.

Mol Cell Biol. 2011-8-1

[3]
T cell Ig and mucin domain-containing protein 3 is recruited to the immune synapse, disrupts stable synapse formation, and associates with receptor phosphatases.

J Immunol. 2013-12-13

[4]
TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway.

PLoS One. 2015-10-22

[5]
Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.

Proc Natl Acad Sci U S A. 2018-2-20

[6]
Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation.

J Exp Med. 2015-12-14

[7]
Murine Tim-1 is excluded from the immunological synapse.

F1000Res. 2012-8-10

[8]
HIV Envelope gp120 Alters T Cell Receptor Mobilization in the Immunological Synapse of Uninfected CD4 T Cells and Augments T Cell Activation.

J Virol. 2016-11-14

[9]
T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation.

Proc Natl Acad Sci U S A. 2005-11-22

[10]
TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8 T cells in conjunction with CEACAM1.

Cell Death Dis. 2021-4-14

引用本文的文献

[1]
Tim-3 Promotes Early Differentiation of Tbet Effector T Cells During Acute Viral Infection.

bioRxiv. 2025-7-11

[2]
High-throughput discovery of transmembrane helix dimers from human single-pass membrane proteins with TOXGREEN sort-seq.

bioRxiv. 2025-5-11

[3]
Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function.

Nat Cell Biol. 2025-5

[4]
CD226 identifies effector CD8 T cells during tuberculosis and costimulates recognition of -infected macrophages.

bioRxiv. 2025-1-24

[5]
Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression.

Eur J Med Res. 2024-12-18

[6]
Myeloid-Derived Suppressor Cells Induce Exhaustion-Like CD8 T Cells during JEV Infection.

Int J Biol Sci. 2024-11-4

[7]
Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy.

Front Immunol. 2024-8-30

[8]
Role of TIM-3 in ovarian cancer: the forsaken cop or a new noble.

Front Immunol. 2024

[9]
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.

Br J Cancer. 2024-10

[10]
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.

Signal Transduct Target Ther. 2024-5-22

本文引用的文献

[1]
Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development.

Exp Mol Med. 2020-5

[2]
Intratumoral Tcf1PD-1CD8 T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.

Immunity. 2019-1-8

[3]
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1CD8 Tumor-Infiltrating T Cells.

Immunity. 2019-1-8

[4]
TIM-3, a promising target for cancer immunotherapy.

Onco Targets Ther. 2018-10-16

[5]
Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome.

Nat Genet. 2018-10-29

[6]
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

Int Immunopharmacol. 2018-7-2

[7]
Chimeric Antigen Receptor Therapy.

N Engl J Med. 2018-7-5

[8]
Regulatory mechanisms in T cell receptor signalling.

Nat Rev Immunol. 2018-8

[9]
Cancer immunotherapy using checkpoint blockade.

Science. 2018-3-23

[10]
Immune regulation by Tim-3.

F1000Res. 2018-3-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索